DiaSorin SpA
http://www.diasorin.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From DiaSorin SpA
Qiagen CFO Sees COVID Diagnostics Volatility Continuing In 2022
Qiagen’s doubled-down focus on PCR technologies in late 2019 proved to be fortuitous, but future growth will come from many other drivers, says CFO Roland Sackers.
Deal Watch: Lilly Teams With Regor On Metabolic Disorders
Chinese firm RareStone licenses Rhythm’s Imcivree in greater China and will help enroll label-expansion studies for the drug. Omeros sells ophthalmic surgery drug Omidria and its commercial team to Rayner Surgical Group.
Medtechs Drive To Keep The Status Quo In A Year Like No Other
The performances of the leading medtechs in the first year of the COVID-19 pandemic were impossible to compare and certainly unrepresentative of normal business cycles and competitive activity. Elective care was largely put on hold and emergency needs boosted exceptional demand for certain product types. More than anything else, 2020 tested management skills and planning.
MTI 100 Review: Medtechs Drive To Keep The Status Quo In A Year Like No Other
The performances of the leading medtechs in the first year of the COVID pandemic were impossible to compare and certainly unrepresentative of normal business cycles and competitive activity. Elective care was largely put on hold and emergency needs boosted exceptional demand for certain product types. More than anything else, 2020 tested management's planning skills.
Company Information
- Industry
-
Medical Devices
- Diagnostic Equipment & Supplies
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Other Names / Subsidiaries
-
- Biotrin International
- DiaSorin Molecuular
- Focus Diagnostics